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GENERAL PRINCIPLES OF TDM
The vast majority of drugs used in clinical practice do not 
require TDM. It is far easier for clinicians to adopt a ‘one size
fits all’ approach to dosing. Alternatively doses may be
modified according to response. However, with some drugs
this will result in high rates of toxicity, or suboptimal efficacy. 
The characteristics that make drugs suitable for TDM include:
■ A narrow therapeutic window
■ Good correlation between drug concentration and effect
or toxicity
■ Variable pharmacokinetics in different individuals
■ The availability of a reliable assay.
Digoxin and the first-line anticonvulsants are examples of
drugs where TDM plays an important role. However, even when
all of these characteristics are present, TDM is seldom done as
a routine part of management for every patient. Clinicians
typically use TDM if there are clinical concerns such as toxicity,
poor efficacy, drug interactions, or special groups at risk of
altered levels. This use of TDM is rational and appropriate, as
there are very few randomised controlled trials to support the
routine use of TDM.
WHICH ANTIRETROVIRALS ARE SUITABLE FOR TDM?
The nucleoside reverse transcriptase inhibitors (NRTIs) are pro-
drugs, which require activation by intracellular phos-
phorylation. There is a poor correlation between plasma NRTI
levels and effect. Only a few laboratories are capable of
measuring intracellular levels. NRTIs are therefore not suitable
for TDM.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
display highly variable pharmacokinetics. The key cytochrome
P450 isoenzyme responsible for metabolising efavirenz,
CYP2B6, has a polymorphism that results in slower
metabolism. This polymorphism occurs much more frequently
in African Americans than Caucasians1 – it is unclear whether
this polymorphism will occur commonly in southern Africa.
There is a correlation between higher plasma levels and
neuropsychiatric adverse effects of efavirenz, and between
lower levels and virological failure.2 A population
pharmacokinetic study has shown that Thai and South African
patients have lower clearance of nevirapine, resulting in
greater exposure, than patients in ‘Western countries’.3 This
may account in part for high rates of nevirapine-induced
hepatotoxicity, particularly among women with a lower body
mass index, reported in a South African study.4 Higher
nevirapine levels are associated with a greater chance of
virological success.5
The protease inhibitors (PIs) also have highly variable
pharmacokinetics. Plasma concentrations of PIs have been
shown to correlate with virological success.6 High levels of
certain PIs correlate with adverse drug reactions, notably
nephrolithiasis with indinavir7 and dyslipidaemia with
lopinavir/ritonavir.8
Therefore both NNRTIs and PIs have many characteristics that
make them potentially suitable candidates for TDM.
ARE RELIABLE ANTIRETROVIRAL ASSAYS
AVAILABLE?
Currently there are no commercial kits to measure drug levels
of antiretrovirals, though a few are in development, so
antiretroviral TDM is conducted by laboratories that have
developed their own in-house assays. It is therefore essential
that laboratories participate in regular quality control to
ensure that their assays are reliable. In a recent survey of
laboratories conducting TDM, only 12 out of 31 had assays
that were in the acceptable range for more than 90% of
measurements.9
LIMITATIONS OF TDM
A number of randomised controlled trials have been conducted 
to assess the value of routine TDM. In these studies patients
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were randomised to control or TDM arms, where the treating
clinician was advised about the antiretroviral level and, if
necessary, to adjust the dose. Two of these studies10,11 showed
higher rates of virological suppression in the TDM arms.
However, a number of other studies have failed to show a
benefit for routine TDM.12,13 One problem encountered in these
randomised trials is that clinicians often did not make the
recommended dose adjustments. In some trials the follow-up
was very short. Lastly, the trials were under-powered. Until a
large trial is conducted to address the weaknesses of the
existing studies, there does not appear to be a role for routine
TDM for all patients treated with antiretrovirals.
A recent study14 found that drug levels, particularly for PIs,
were very variable in individual patients sampled at different
times. This could partly be explained by the variability in the
effect of dosing with food, which is important for the PIs
studied. In addition, adherence can clearly affect drug levels;
indeed, TDM is one tool to detect poor adherence. Controlling
for adherence is difficult in clinical practice. This study14
highlights the importance of not making major clinical
decisions on the basis of a single TDM result.
PATIENTS AT HIGHER RISK OF DRUG LEVELS 
OUTSIDE REFERENCE RANGES
Given that current evidence does not support routine TDM, it 
makes sense to utilise TDM in patients at particular risk for
either suboptimal or toxic levels. 
CHILDREN
Several important physiological changes in childhood,
particularly early childhood, affect the pharmacokinetics of
drugs.15 Firstly, the volume of distribution is affected as total
body water is high in neonates and remains high in young
children. Neonates have impaired drug absorption, metabolism
and excretion, while in young children these parameters are
enhanced compared with adults. Many authorities therefore
recommend TDM in young children, especially as there are very
limited data available for most antiretrovirals in children.
PREGNANCY
Many physiological changes in pregnancy affect pharma-
cokinetics:16
■ Increased GIT motility
■ Decreased protein binding
■ Increased volume of distribution (fat and water)
■ Mild hepatic enzyme induction
■ Increased renal excretion.
Up to a third of pregnant epileptics experience an increased
frequency of seizures owing to sub-therapeutic anticonvulsant
levels, illustrating that these physiological changes of
pregnancy are clinically relevant. A recent study showed lower
lopinavir levels in pregnant women.17 Despite this, the women
still had good virological suppression. This change in PI levels
induced by pregnancy is likely to be relevant when a degree of
PI resistance is present – TDM should be considered in this
setting.
DRUG INTERACTIONS
Many PIs are substrates of the important drug transporter,
P glycoprotein. Their levels can be affected by drugs that
inhibit or induce P glycoprotein. PIs and NNRTIs are
metabolised by the cytochrome P450 system, and their levels
can be affected by drugs that inhibit or induce this system. If
a drug known to have such interactions has to be co-
administered, TDM should be considered.
LIVER DISEASE
PIs and NNRTIs are metabolised by the cytochrome P450
system, which occurs primarily in the liver. Unlike renal
disease, there is no accurate biochemical marker to indicate
how much hepatic impairment is present. TDM should
therefore be considered for patients with evidence of liver
failure, as they may experience toxicity due to high levels.
INTEGRATING TDM AND PI RESISTANCE DATA –
WHAT’S THE IQ?
PI resistance can to a certain extent be overcome by
increasing the levels. It therefore makes sense to integrate the
resistance data and the drug level. This is done using the
inhibitory quotient (IQ), which is calculated by dividing the
trough level by a factor, depending on the resistance test
conducted. This is typically a genotypic test, and the trough
level is divided by the number of major PI mutations. This
genotypic IQ has been shown to correlate with virological
success in PI-experienced patients.18
Note that this strategy cannot be used with the NNRTIs, as a
single mutation generally confers very high-level resistance,
which cannot be overcome by increasing the dose.
A ROLE FOR TDM IN SOUTHERN AFRICA?
Antiretroviral TDM could play an important adjunctive role in
our area. Clearly this will be a limited resource, confined to
high-risk patients or to those with some degree of PI
resistance. There is a danger that laboratories will offer TDM
without the necessary quality assurance. Until commercial kits
become available, TDM should only be conducted by specialist
pharmacology laboratories that participate in regular quality
assurance.
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